(Press-News.org) A living ink containing bacteria attracts coral larvae and could help rebuild reefs. Corals are struggling with water pollution, as well as warming and acidification caused by climate change. One way to support coral reef persistence is to encourage coral recruitment onto the reef. Coral larvae are free-swimming animals that eventually settle onto a surface and transform into a polyp with a hard, durable body. Certain bacteria secrete chemical cues that stimulate settlement and metamorphosis. Settled polyps may then reproduce asexually, expanding the size of the reef. Daniel Wangpraseurt and colleagues created a living material that encourages coral larvae to attach and settle down. Bacterial Reef Ink (BRINK) is a photopolymerized hydrogel hosting two native Hawaiian settlement-inducing bacterial strains, Cellulophaga lytica and Thalassotalea euphylliae. In test tanks, coral settlement on surfaces coated with BRINK was fivefold higher than on surfaces without ink for one coral species and fourfold higher for a different coral species. According to the authors, the ink could be customized to support a range of settlement-inducing bacteria tailored to specific coral reef environments worldwide.
END
Bacterial ink to restore coral reefs
2025-09-09
ELSE PRESS RELEASES FROM THIS DATE:
AI-based satellite count of migrating wildebeest
2025-09-09
An AI-powered satellite counting effort conducted over two years concludes that less than 600,000 wildebeest migrate across the Serengeti-Mara ecosystem each year—half of previous estimates from manned aircraft surveys. Lions, hyenas, crocodiles, and tourism professionals all rely on the annual migration of wildebeest (Connochaetes taurinus) which transit through Kenya and Tanzania as the herds follow the seasonal growth of grass. Prior estimates of the migratory wildebeest population that make the trek each year were reached by extrapolating counts from aerial photos in the south of the ecosystem. Isla Duporge and colleagues ...
Bee-sting inspired microneedles from Chung-Ang University could revolutionize drug delivery
2025-09-09
Neurological diseases affect millions worldwide, and the need for long-term patient-friendly treatments has never been greater. While needle-based injections are the standard for most therapies, regular drug injections can often be painful and inconvenient. Microneedles—which are tiny, micron-sized needle systems— have emerged as a promising alternative to conventional needles and offer a pain free way to deliver medicines. However, most existing microneedles are rigid and can cause discomfort during prolonged use and therefore limits their adoption in long-term use.
To overcome this, researchers from South Korea have designed a new microneedles system inspired by the ...
Pusan National University researchers reveal how uneven ocean warming is altering propagation of the Madden-Julian oscillation
2025-09-09
The Earth’s tropical regions drive some of the most powerful weather and climate variability globally. Among these, the Madden–Julian Oscillation (MJO) is a dominant intraseasonal climate signal, characterized by large clusters of clouds and rainfall that slowly move eastward across the warm tropical oceans. In doing so, the MJO shapes rainfall patterns, influences tropical cyclones, modulates monsoons, and even impacts weather far beyond the tropics. Understanding the factors that govern its ...
Mapping causality in neuronal activity: towards a better understanding of brain networks
2025-09-09
Understanding the brain’s functional architecture is a fundamental challenge in neuroscience. The connections between neurons ultimately dictate how information is processed, transmitted, stored, and retrieved, thus forming the basis of our cognitive functions. Scientists often study neuronal signaling by recording the brief electrical pulses they generate over time, often referred to as ‘spike trains.’
Because of their bursty and aperiodic nature, inferring causal relationships between spike trains recorded from different neurons remains ...
New research identifies IFITM3 as key driver of immunotherapy response in small cell lung cancer
2025-09-09
(Barcelona, Spain September 9, 2025 1 p.m. CEST / UTC +2) — New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.
The research was presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
SCLC tumors are typically characterized by low expression of major histocompatibility complex class I (MHC-I), which impairs ...
Scientists find curvy answer to harnessing “swarm intelligence”
2025-09-09
Birds flock in order to forage and move more efficiently. Fish school to avoid predators. And bees swarm to reproduce. Recent advances in artificial intelligence have sought to mimic these natural behaviors as a way to potentially improve search-and-rescue operations or to identify areas of wildfire spread over vast areas—largely through coordinated drone or robotic movements. However, developing a means to control and utilize this type of AI—or “swarm intelligence”—has proved challenging.
In a newly published paper, an international team of scientists describes a framework designed to advance swarm intelligence—by controlling flocking and ...
PALOMA-2 study: Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC
2025-09-09
(Barcelona, Spain--September 9, 2025 at 11:30 AM CEST / UTC +2)— A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).
The results were presented at the International Association for the Study of Lung Cancer at the 2025 World Conference on Lung Cancer (WCLC).
In the fully enrolled Cohort 5 of the PALOMA-2 trial, the Q4W dosing regimen was shown to maintain similar efficacy compared ...
First 3D real-time imaging of hydrogen’s effect on stainless steel defects opens the way to a safer hydrogen economy
2025-09-09
A study led by University of Oxford and Brookhaven National Laboratory researchers has uncovered how exposure to hydrogen atoms dynamically alters the internal structure of stainless steel.
The findings reveal that hydrogen allows internal defects in steel to move in ways not normally possible – which can lead to unexpected failure.
This discovery offers vital insights that could help make hydrogen fuel systems safer and more reliable, from aircraft and fusion reactors to pipelines and storage tanks.
The study has been published today (9 Sept) ...
Circulating tumor DNA may guide immunotherapy use in limited-stage SCLC, new study shows
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).
The research, led by scientists at the National Cancer Center of China, assessed ctDNA in 177 patients with LS-SCLC treated with chemoradiotherapy (CCRT), 77 of whom received consolidation immune checkpoint inhibitors (ICIs). Circulating tumor DNA was measured ...
Novel immunotherapy strategy shows promising long-term survival in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors
2025-09-09
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) – A new study presented today reports encouraging long-term survival outcomes from an experimental viral immunotherapy, CAN-2409, in patients with advanced non-small cell lung cancer (NSCLC) who previously failed to respond adequately to immune checkpoint inhibitors (ICI).
The study was presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
The phase 2a clinical trial investigated the efficacy of two intratumoral injections of CAN-2409 combined with an oral prodrug (valacyclovir) in ...